Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBT (2020 - 2025)

Bioventus (BVS) has disclosed EBT for 6 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 26784.91% year-over-year to $14.1 million, compared with a TTM value of $25.7 million through Dec 2025, up 149.12%, and an annual FY2025 reading of $25.7 million, up 149.12% over the prior year.
  • EBT was $14.1 million for Q4 2025 at Bioventus, up from $4.7 million in the prior quarter.
  • Across five years, EBT topped out at $24.5 million in Q2 2021 and bottomed at -$130.6 million in Q4 2022.
  • Average EBT over 5 years is -$16.4 million, with a median of -$5.4 million recorded in 2024.
  • The sharpest move saw EBT plummeted 4043.38% in 2022, then soared 26784.91% in 2025.
  • Year by year, EBT stood at -$2.8 million in 2021, then crashed by 1079.64% to -$32.4 million in 2022, then skyrocketed by 74.09% to -$8.4 million in 2023, then soared by 99.37% to -$53000.0 in 2024, then skyrocketed by 26784.91% to $14.1 million in 2025.
  • Business Quant data shows EBT for BVS at $14.1 million in Q4 2025, $4.7 million in Q3 2025, and $10.3 million in Q2 2025.